Clinical trials
Castrate Resistant Prostate Cancer clinical trials
Below are recruiting castrate resistant prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 291 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03851640RecruitingPhase 3
Study drug for advanced prostate cancer that kept spreading despite standard treatments
This Phase 3 study tests HC-1119 soft capsules in men with metastatic castration-resistant prostate cancer—cancer that keeps progressing even when testosterone is blocked. It aims to see whether the drug works better than expected and is safe, especially after prior treatments like abiraterone and/or docetaxel.
ShanghaiAges 18 years+ - NCT07311694RecruitingPhase 3
Comparing a new treatment with standard drugs for advanced prostate cancer
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07302763Recruiting
PET imaging to track prostate cancer changes
This study uses special PET scans (up to 4 times) to see how metastatic prostate cancer changes over time. It is for people whose cancer has spread and is still growing after hormone treatments, and who are planning to start chemotherapy or PSMA therapy.
Québec, QuebecAges 18 years+ - NCT07298239RecruitingEarly Phase 1
CAR-NK cell therapy for advanced prostate cancer
This trial tests a new immune cell therapy (CAR-NK cells) made from a healthy donor's cells. It is designed to attack prostate cancer that has spread and become resistant to hormone therapy, especially if your cancer cells have the PSMA protein.
Beijing, 不限Ages 18 years+ - NCT07288359RecruitingPhase 1/Phase 2
Study of GVV858 for HR+/HER2- breast cancer and other solid tumors
This trial is testing a new drug, GVV858, either alone or with hormone therapy, for people with HR+/HER2- advanced breast cancer or certain other advanced solid tumors. It may be an option if standard treatments are no longer working or available.
Atlanta, GeorgiaAges 18 years+ - NCT07287150RecruitingPhase 2
Testing Inavolisib for advanced prostate cancer
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
Los Angeles, CaliforniaAges 18 years+ - NCT07259213RecruitingPhase 1/Phase 2
Study of a new drug (161Tb-RAD402) for men with advanced prostate cancer
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
Wollongong, New South WalesAges 18 years+ - NCT07258407RecruitingPhase 1/Phase 2
TD001 for men with PSMA-positive metastatic prostate cancer
This trial tests a new drug, TD001, in men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It aims to see if TD001 is safe and effective against tumors that show a specific marker called PSMA.
New Haven, ConnecticutAges 18 years+ - NCT07250542RecruitingPhase 2
Fasudil with immunotherapy for advanced prostate cancer
This trial tests a combination of fasudil hydrochloride and immunotherapy for men with metastatic castration-resistant prostate cancer that has stopped responding to chemotherapy and hormone therapy. The goal is to see if this new approach can help control the cancer.
NanjingAges 18–85 - NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT07244393RecruitingPhase 1
Combination therapy for advanced prostate cancer
This trial tests a new combination therapy for advanced prostate cancer that has stopped responding to standard hormone treatments. It combines a radioactive targeted treatment (Lutetium-177 DGUL) with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors and slow the cancer's growth.
SeoulAges 19 years+ - NCT07240857Enrolling by invitationEarly Phase 1
CAR-T cell injection for advanced prostate cancer
This trial tests a new treatment called ACT#001 CAR-T cells, given as a local injection, for prostate cancer that has stopped responding to hormone therapy. It aims to see if this therapy is safe and can help shrink tumors.
Hangzhou, ZhejiangAges 18 years+ - NCT07226713RecruitingPhase 2
Pacritinib for advanced prostate cancer after hormone therapy failure
This trial tests a drug called pacritinib for men with metastatic prostate cancer that has stopped responding to hormone therapies. It aims to see if blocking the JAK2/STAT5 pathway can slow cancer growth.
Milwaukee, WisconsinAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Chandler, ArizonaAges 18 years+ - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Goodyear, ArizonaAges 18 years+ - NCT07219147RecruitingPhase 1
Combination treatment for advanced prostate cancer
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
Duarte, CaliforniaAges 18 years+ - NCT03903835RecruitingPhase 3
Biomarker-guided treatment for metastatic prostate cancer
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
AalstAges 18 years+ - NCT06480110RecruitingPhase 1/Phase 2
Ebastine plus docetaxel for advanced prostate cancer
This trial tests if combining the allergy drug ebastine with the chemotherapy docetaxel can help men with advanced prostate cancer that has stopped responding to hormone therapy. It may offer a new treatment option for those whose cancer is still growing.
CopenhagenAges 18 years+ - NCT07206056RecruitingPhase 1/Phase 2
Study of tulmimetostat and luxdegalutamide for advanced prostate cancer
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
Denver, ColoradoAges 18 years+ - NCT06702995RecruitingPhase 1/Phase 2
Study of XNW5004 plus enzalutamide for advanced prostate cancer
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Jinan, ShandongAges 18 years+ - NCT07200830RecruitingPhase 3
Testing different schedules of a targeted radiation drug for advanced prostate cancer
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
Anchorage, AlaskaAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Sarasota, FloridaAges 18 years+ - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Orlando, FloridaAges 18 years+
Hear when a new Castrate Resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for castrate resistant prostate cancer?
- Yes. Clin2 currently lists 291 recruiting castrate resistant prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a castrate resistant prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a castrate resistant prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-resistant Prostate Cancer
- Castration-resistant Prostate Cancer
- Castrate Sensitive Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.